Revenue (Details) - Schedule of revenues - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Capitalized Costs of Unproved Properties Excluded from Amortization [Line Items]
Revenue	$ 9,641,925	$ 10,866,449
Domestic Pharmaceuticals [Member]
Capitalized Costs of Unproved Properties Excluded from Amortization [Line Items]
Revenue	9,641,925	9,132,216
Export Medical Test Kits [Member]
Capitalized Costs of Unproved Properties Excluded from Amortization [Line Items]
Revenue		$ 1,734,233